Dyne Therapeutics

DYNPhase 3

Dyne Therapeutics is focused on developing life-transforming therapies for patients with genetically driven muscle diseases through its proprietary FORCE™ (Fragment, Oligonucleotide, Conjugate) platform. This platform enables the targeted delivery of therapeutic payloads to muscle tissue, addressing the root cause of diseases with high unmet need. The company has rapidly advanced multiple candidates into clinical development, with promising early data demonstrating target engagement and biomarker correction. Dyne's strategic approach combines validated oligonucleotide modalities with tissue-specific targeting to overcome historical delivery challenges in muscle disorders.

Market Cap

$2.9B

Employees

100-200

Focus

Biotech

DYN · Stock Price

USD 17.56+9.05 (+106.35%)

Historical price data

AI Company Overview

Technology Platform

FORCE™ (Fragment, Oligonucleotide, Conjugate) platform, a proprietary technology that uses antibody fragments targeting transferrin receptor 1 (TfR1) to deliver therapeutic oligonucleotides specifically to muscle tissue.

Pipeline Snapshot

3 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
DYNE-101 + Placebo	Myotonic Dystrophy Type 1 (DM1)	Phase 3
DYNE-251 + Placebo	Duchenne Muscular Dystrophy (DMD)	Phase 1/2
DYNE-101 + Placebo	Myotonic Dystrophy Type 1 (DM1)	Phase 1/2

Funding History

Total raised: $615M

PIPE$325MEcoR1 CapitalSep 15, 2023

IPO$180MUndisclosedAug 13, 2020

Series B$60MMPM CapitalJun 15, 2019

Series A$50MAtlas VentureJan 15, 2018

Opportunities

Dyne's primary growth opportunities lie in successfully advancing its three clinical programs to approval, which would address multi-billion dollar markets with high unmet need.

Further platform validation could enable expansion into other muscle diseases (e.g., other muscular dystrophies, cardiomyopathies) and potentially other tissues by swapping the targeting moiety.

Risk Factors

Key risks include clinical trial failures, emergence of significant safety issues with the TfR1-targeting platform, intense competition from established and emerging players, and the challenges of commercializing high-cost therapies in rare disease markets.

The company remains pre-revenue and reliant on capital markets for funding.

Competitive Landscape

Dyne faces competition from companies like Sarepta (DMD), Avidity Biosciences (FSHD/DM1), and others. Its main differentiation is the FORCE™ targeted delivery platform, which aims to achieve superior muscle delivery and therapeutic index compared to untargeted oligonucleotide approaches, potentially leading to better efficacy and safety profiles.

Publications

Patents

Pipeline